Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/AZD3293> ?p ?o }
Showing triples 1 to 44 of
44
with 100 triples per page.
- AZD3293 abstract "AZD3293, also known as LY3314814 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the build up of beta-amyloid and may help slow or stop Alzheimer's disease.In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop AZD3293. A pivotal Phase II/III clinical trial of AZD3293 started in late 2014 and is planned to recruit 1,500 patients and end in May 2019.".
- AZD3293 thumbnail AZD3293.svg?width=300.
- AZD3293 wikiPageID "44734239".
- AZD3293 wikiPageLength "2064".
- AZD3293 wikiPageOutDegree "10".
- AZD3293 wikiPageRevisionID "642521481".
- AZD3293 wikiPageWikiLink Alzheimers_disease.
- AZD3293 wikiPageWikiLink Amyloid_beta.
- AZD3293 wikiPageWikiLink AstraZeneca.
- AZD3293 wikiPageWikiLink Beta-amyloid.
- AZD3293 wikiPageWikiLink Beta-secretase_1.
- AZD3293 wikiPageWikiLink Category:Alkynes.
- AZD3293 wikiPageWikiLink Category:Alzheimers_disease.
- AZD3293 wikiPageWikiLink Category:Enzyme_inhibitors.
- AZD3293 wikiPageWikiLink Category:Imidazoles.
- AZD3293 wikiPageWikiLink Category:Pyridines.
- AZD3293 wikiPageWikiLink Eli_Lilly_and_Company.
- AZD3293 wikiPageWikiLinkText "AZD3293".
- AZD3293 hasPhotoCollection AZD3293.
- AZD3293 imagefile "AZD3293.svg".
- AZD3293 imagesize "200".
- AZD3293 othernames "LY3314814".
- AZD3293 systematicname "-60.0".
- AZD3293 wikiPageUsesTemplate Template:Chembox.
- AZD3293 wikiPageUsesTemplate Template:Reflist.
- AZD3293 subject Category:Alkynes.
- AZD3293 subject Category:Alzheimers_disease.
- AZD3293 subject Category:Enzyme_inhibitors.
- AZD3293 subject Category:Imidazoles.
- AZD3293 subject Category:Pyridines.
- AZD3293 hypernym Inhibitor.
- AZD3293 type ChemicalCompound.
- AZD3293 type ChemicalSubstance.
- AZD3293 type ChemicalObject.
- AZD3293 type Thing.
- AZD3293 type Q11173.
- AZD3293 comment "AZD3293, also known as LY3314814 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the build up of beta-amyloid and may help slow or stop Alzheimer's disease.In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop AZD3293. A pivotal Phase II/III clinical trial of AZD3293 started in late 2014 and is planned to recruit 1,500 patients and end in May 2019.".
- AZD3293 label "AZD3293".
- AZD3293 sameAs m.012hd30d.
- AZD3293 sameAs Q19903502.
- AZD3293 sameAs Q19903502.
- AZD3293 wasDerivedFrom AZD3293?oldid=642521481.
- AZD3293 depiction AZD3293.svg.
- AZD3293 isPrimaryTopicOf AZD3293.